S&P, Nasdaq edge higher with gold spike, FOMC minutes in focus
CAMBRIDGE, England - Bicycle Therapeutics plc (NASDAQ:BCYC) announced Monday the appointment of Roger Dansey, M.D., and Hervé Hoppenot to its Board of Directors, bringing significant oncology expertise to the pharmaceutical company developing bicyclic peptide-based therapeutics. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 10.39 and more cash than debt on its balance sheet, though analysts note the company is quickly burning through its cash reserves.
Dansey, who currently serves on the boards of Inovio Inc. and Ottimo Pharma, previously held positions as interim chief oncology officer and chief development officer at Pfizer Oncology. He also served as chief medical officer and president of research and development at Seagen before its acquisition by Pfizer. Throughout his career at companies including Merck, Gilead Sciences, and Amgen, Dansey contributed to the development and approval of several cancer therapies including Keytruda and Padcev.
Hoppenot joins the board after serving 11 years as chairman and CEO of Incyte, where he oversaw the company’s growth from $350 million to $4.2 billion in revenue. He previously served as president of Novartis Oncology and held senior roles at Rhône Poulenc (later Aventis). He currently serves on the boards of Pierre Fabre Laboratories and N-Power Medicine.
"As prominent leaders in oncology research, drug development and commercialization who have delivered many transformative cancer medicines to patients, Roger and Hervé will add valuable perspectives and expertise," said Bicycle Therapeutics CEO Kevin Lee in the press release statement.
Bicycle Therapeutics is advancing several clinical-stage candidates, including zelenectide pevedotin targeting Nectin-4, BT5528 targeting EphA2, and BT7480, a tumor-targeted immune cell agonist targeting Nectin-4 and CD137.
The company, headquartered in Cambridge, UK, with key functions in Cambridge, Massachusetts, is developing synthetic short peptides constrained with small molecule scaffolds designed to bind targets with high affinity and selectivity. For deeper insights into BCYC’s financial health, growth prospects, and over 30 key financial metrics, investors can access the comprehensive Pro Research Report available exclusively on InvestingPro, which covers what really matters for informed investment decisions.
In other recent news, Bicycle Therapeutics has been the focus of analyst adjustments following their second-quarter 2025 earnings report. RBC Capital raised its price target for the company from $25 to $27, maintaining an Outperform rating. This adjustment came after discussions with Bicycle Therapeutics’ management, highlighting confidence in the company’s future prospects. Conversely, Citizens JMP lowered its price target for Bicycle Therapeutics from $22 to $10, although it also maintained a Market Outperform rating. The firm cited a revised valuation based on discounted EPS and revenue multiple analysis. These differing perspectives underscore the varied analyst views on the company’s financial outlook. Investors may find these updates significant as they consider their positions in Bicycle Therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.